Expertise in
7
conditions

Dr. Alvaro Moreno-Aspitia

Hematology | Oncology
Mayo Clinic Hospital In Florida
4500 San Pablo Rd S, 
Jacksonville, FL 
Expertise in
7
conditions
Mayo Clinic Hospital In Florida
4500 San Pablo Rd S, 
Jacksonville, FL 

Overview

Alvaro Moreno-Aspitia is a Hematologist and an Oncologist practicing medicine in Jacksonville, Florida.

Dr. Moreno-Aspitia is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.

He is actively involved in clinical research, co-authoring 75 peer reviewed articles and participating in 11 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Mayo Clinic Hospital In Florida
4500 San Pablo Rd S, Jacksonville, FL 32224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

MC1633 Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy
MC1633 Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy
Enrollment Status: Completed
Publish Date: July 01, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: FASN Inhibitor TVB-2640, Paclitaxel, Trastuzumab
Study Phase: Phase 2
Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer
Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 30, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Cyclophosphamide, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim
Study Phase: Phase 2
Prospective Study to Evaluate the Role of Tumor Sequencing in Women Receiving Palbociclib for Advanced Hormone Receptor (HR)-Positive, Breast Cancer (PROMISE)
Prospective Study to Evaluate the Role of Tumor Sequencing in Women Receiving Palbociclib for Advanced Hormone Receptor (HR)-Positive, Breast Cancer (PROMISE)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Procedure, Other
Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer
Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 12, 2026
Intervention Type: Procedure, Biological
Study Drug: Therapeutic Estradiol
Study Phase: Phase 2
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Pharmacodynamic Study of Estrogen Suppression Threshold-Directed Therapy (ESTDT) of Anastrozole as Adjuvant Therapy for Early Stage Breast Cancer
Pharmacodynamic Study of Estrogen Suppression Threshold-Directed Therapy (ESTDT) of Anastrozole as Adjuvant Therapy for Early Stage Breast Cancer
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Drug
Study Drugs: Anastrozole, Letrozole
Study Phase: Phase 2
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drugs: GSK525762, Fulvestrant
Study Phase: Phase 1
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: Binimetinib, Palbociclib, Trifluridine+Tipiracil Hydrochloride
Study Phase: Phase 2
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: August 20, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Enrollment Status: Withdrawn
Publish Date: May 26, 2022
Intervention Type: Drug, Biological
Study Drugs: Abemaciclib, Trastuzumab Emtansine
Study Phase: Phase 2
View 9 Less Clinical Trials

75 Total Publications

Long-term cellular and humoral responses to SARS-CoV-2 vaccinations in patients with solid malignancies undergoing chemotherapy.
Long-term cellular and humoral responses to SARS-CoV-2 vaccinations in patients with solid malignancies undergoing chemotherapy.
Journal: Frontiers in immunology
Published: August 22, 2025
Similar Doctors
Expertise in
23
conditions
Dr. Talha Badar
Hematology | Oncology
Expertise in
23
conditions
Dr. Talha Badar
Hematology | Oncology
Referral may be required

Mayo Clinic Hematology & Oncology

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-7188
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Talha Badar is a Hematologist and an Oncologist practicing medicine in Jacksonville, Florida. Dr. Badar is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Badar is currently accepting new patients.

Expertise in
31
conditions
Expertise in
31
conditions
Referral may be required

Mayo Clinic Hematology & Oncology

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-7188
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Foran is an Oncologist practicing medicine in Jacksonville, Florida. Dr. Foran is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Colonoscopy. Dr. Foran is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Mayo Clinic Hematology & Oncology

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-7188
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sikander Ailawadhi is an Oncologist practicing medicine in Jacksonville, Florida. Dr. Ailawadhi is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Colonoscopy. Dr. Ailawadhi is currently accepting new patients.

Frequently Asked Questions about Dr. Alvaro Moreno-Aspitia

How do I make an appointment with Dr. Alvaro Moreno-Aspitia?

You can book an appointment with Dr. Alvaro Moreno-Aspitia by calling their office at 904-953-2000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Alvaro Moreno-Aspitia a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Alvaro Moreno-Aspitia is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Alvaro Moreno-Aspitia specialize in?

While Dr. Alvaro Moreno-Aspitia is a Hematology, they have specific expertise in Breast Cancer, HER-2 Positive Breast Cancer, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Alvaro Moreno-Aspitia participate in research or clinical trials?

Yes. Dr. Alvaro Moreno-Aspitia has published 75 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Alvaro Moreno-Aspitia's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Alvaro Moreno-Aspitia accept my insurance?

Dr. Alvaro Moreno-Aspitia accepts most major insurance plans, including Blue Cross Blue Shield and Medicare. We recommend calling the office directly at 904-953-2000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moreno-Aspitia's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile